KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Treasury Shares (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Treasury Shares for 13 consecutive years, with $19.4 billion as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares rose 19.7% year-over-year to $19.4 billion; the TTM value through Mar 2026 reached $19.4 billion, up 19.7%, while the annual FY2025 figure was $18.6 billion, 22.72% up from the prior year.
  • Treasury Shares hit $34.7 million in Q1 2026 for Regeneron Pharmaceuticals, up from $33.7 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $34.7 million in Q1 2026 and bottomed at $300000.0 in Q1 2024.
  • Average Treasury Shares over 5 years is $20.0 million, with a median of $25.1 million recorded in 2023.
  • Year-over-year, Treasury Shares surged 33.79% in 2022 and then increased 14.36% in 2024.
  • Regeneron Pharmaceuticals' Treasury Shares stood at $10.4 billion in 2022, then grew by 21.32% to $12.6 billion in 2023, then grew by 20.76% to $15.2 billion in 2024, then rose by 22.72% to $18.6 billion in 2025, then increased by 4.3% to $19.4 billion in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $19.4 billion, $18.6 billion, and $17.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.